Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 83

Sort by

Sort Order Select

Journal Articles

Bone Loss and High Bone Turnover in Patients with Non-Hodgkin's Lymphoma Who Receive Frontline Chemotherapy: Final Results of a Multicenter Prospective Study

Evangelos Terpos, MD PhD, Despina Fotiou, MD, Konstantinos Anargyrou, MD, Theodoros P. Vassilakopoulos, MD PhD, Dimitrios Christoulas, MD, Polyzois Makras, MD PhD, Maria Dimou, MD PhD, Ioannis Ntanasis-Stathopoulos, MD, Stavroula Masouridou, MD, Maria K. Angelopoulou, MD, Athanasios Papatheodorou, PhD, Konstantinos Tsionos, MD, Panayiotis Panayiotidis, MD, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_1): 4124.

https://doi.org/10.1182/blood-2019-123615

Published: 2019

Journal Articles

Impact of Daratumumab Monotherapy on Bone Parameters in Patients with Relapsed and/or Refractory Multiple Myeloma Who Have Received at Least 2 Prior Lines of Therapy Including Lenalidomide and a Proteasome Inhibitor; Interim Analysis of a Phase 2 Study (the REBUILD Study)

Evangelos Terpos, MD PhD, Eftathios Kastritis, Evdoxia Hatjiharissi, Eirini Katodritou, MD, Evangelos Eleutherakis-Papaiakovou, MD, Evgenia Verrou, MD, Maria Gavriatopoulou, MD, Alexandros Leonidakis, PhD, Ioannis Ntanasis-Stathopoulos, MD, Sosana Delimpasi, MD, Marie-Christine Kyrtsonis, MD PhD, Maria Papaioannou, Argiris Symeonidis, MD PhD, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_1): 1837.

https://doi.org/10.1182/blood-2019-124638

Published: 2019

Journal Articles

Consolidation with Carfilzomib, Lenalidomide and Dexamethasone (KRd) Following ASCT Results in High Rates of Minimal Residual Disease Negativity and Improves Bone Metabolism, in the Absence of Bisphosphonates, Among Newly Diagnosed Patients with Multiple Myeloma

Maria Gavriatopoulou, MD, Evangelos Terpos, MD PhD, Ioannis Ntanasis-Stathopoulos, MD, Panagiotis Malandrakis, MD, Evangelos Eleutherakis-Papaiakovou, MD, Athanasios Papatheodorou, PhD, Nikolaos Kanellias, MD, Magdalini Migkou, MD, Despina Fotiou, MD, Ioanna Dialoupi, MD, Maria Roussou, MD, Nikoletta-Aikaterini Kokkali, Eftathios Kastritis, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_1): 3118.

https://doi.org/10.1182/blood-2019-123916

Published: 2019

Journal Articles

Myelofibrosis osteoclasts are clonal and functionally impaired

Ivo Veletic, Taghi Manshouri, Asha S. Multani, C. Cameron Yin, Lei Chen, Srdan Verstovsek, Zeev Estrov

Blood (2019) 133 (21): 2320–2324.

https://doi.org/10.1182/blood-2018-10-878926

Published: 2019

Includes: Supplemental data

Journal Articles

Depletion of Mature B Cells By Anti CD20-Directed Antibody Induces Trabecular Bone Loss in Young Mice: An Alert for Clinicians?

Albert Kolomansky, MD, Naamit Deshet-Unger, PhD, Alina Ostrovsky, Nathalie Ben-Califa, PhD, Sahar Hiram-Bab, PhD, Tamar Liron, PhD, Howard S. Oster, MD PhD, Moshe Mittelman, MD, Yankel Gabet, DMD, PhD, Drorit Neumann, PhD

Blood (2017) 130 (Supplement 1): 5642.

https://doi.org/10.1182/blood.V130.Suppl_1.5642.5642

Published: 2017

Journal Articles

Phase 2 Study of Carfilzomib and Bone Metabolism in Patients with Relapsed Multiple Myeloma

Attaya Suvannasankha, MD, Rafat Abonour, MD, Sherif Farag, MD PhD, Rebecca W. Silbermann, MD, Sariya Wongsaengsak, MD, Mary Helen Cangany, RN, Anita Rush-Taylor, RN, Mark Tann, MD, Sandra K Althouse, PhD, Susan M Perkins, PhD, G David Roodman, MD PhD

Blood (2017) 130 (Supplement 1): 1826.

https://doi.org/10.1182/blood.V130.Suppl_1.1826.1826

Published: 2017

Journal Articles

The Combination of Radium-223 Dichloride and Bortezomib Effectively Reduces Tumor Burden and Lesion Area in the Syngeneic, Systemic 5TGM1 Multiple Myeloma Mouse Model

Mari Suominen, Tiina Kähkönen, Jenni Mäki-Jouppila, Jukka P Rissanen, Anniina Luostarinen, Katja M Fagerlund, Birgitta Sjöholm, Esa Alhoniemi, Sanna Kakonen, PhD, Gerhard Siemeister, Dominik Mumberg, Jussi M Halleen, Karl Ziegelbauer, Arne Scholz

Blood (2017) 130 (Supplement 1): 1802.

https://doi.org/10.1182/blood.V130.Suppl_1.1802.1802

Published: 2017

Journal Articles

Low Intensity Vibration Treatment Reduces Myeloma Cell-Induced Osteoclast Formation By Inhibiting IL-6 and GFI-1 Production By MM Cells

Gabriel M. Pagnotti, PhD, Noriyoshi Kurihara, DDS, PhD, G David Roodman, MD PhD

Blood (2017) 130 (Supplement 1): 1775.

https://doi.org/10.1182/blood.V130.Suppl_1.1775.1775

Published: 2017

Journal Articles

The Exosomes-Derived EGFR Ligand Amphiregulin (AREG) Is a New Pro-Osteoclastogenic Factor in Multiple Myeloma

Emanuela Vicario, PhD, Stefania Raimondo, PhD, Laura Saieva, PhD, Federica Costa, PhD, Vincenza Tinnirello, Fabrizio Accardi, MD, Franco Aversa, MD, Nicola Giuliani, MD PhD, Riccardo Alessandro, PhD

Blood (2017) 130 (Supplement 1): 1776.

https://doi.org/10.1182/blood.V130.Suppl_1.1776.1776

Published: 2017

Journal Articles

CCL3 Signaling Is Essential for Leukemia Progression but Dispensable for Hematopoietic Stem Cell Maintenance

Rhonda J. Staversky, BS, Mary A Georger, B.S., Marian Ackun-Farmmer, B.S., Michael W. Becker, MD, Danielle S.W. Benoit, PhD, Laura M. Calvi, MD, Benjamin J. Frisch, PhD

Blood (2017) 130 (Supplement 1): 2603.

https://doi.org/10.1182/blood.V130.Suppl_1.2603.2603

Published: 2017

Journal Articles

Transdifferentiation of Bone Marrow Pro-B Cells into Bone-Resorbing Osteoclasts- an Unexpected Role for Erythropoietin

Naamit Deshet-Unger, MSc, Sahar Hiram-Bab, PhD, Nathalie Ben-Califa, PhD, Dafna Gilboa, MSc, Tamar Liron, PhD, Kolomansky Albert, MD, Howard S Oster, MD PhD, Moshe Mittelman, MD, Yankel Gabet, DMD, PhD, Drorit Neumann, PhD

Blood (2016) 128 (22): 5043.

https://doi.org/10.1182/blood.V128.22.5043.5043

Published: 2016

Journal Articles

Lenalidomide, Adriamycin, and Dexamethasone (RAD) As Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma Who Are Eligible for Autologous Transplantation (ASCT): A Phase 2 Study from the Greek Myeloma Study Group

Evangelos Terpos, Eirini Katodritou, Argiris Symeonidis, Flora Zagouri, Antonis Gerofotis, Georgia Christopoulou, Maria Gavriatopoulou, Dimitrios Christoulas, Alexandra Kourakli, Pavlina Konstantinidou, Efstathios Kastritis, MD, Meletios A Dimopoulos

Blood (2016) 128 (22): 4488.

https://doi.org/10.1182/blood.V128.22.4488.4488

Published: 2016

Journal Articles

MSMD Patients with IFN-g-STAT1 Signaling Defect Present Enhanced Osteoclastogenesis and Bone Resorption

Shiho Nishimura, MD, Miyuki Tsumura, PhD, Osamu Hirata, MD PhD, Reiko Kagawa, MD, Yoko Mizoguchi, MD PhD, Satoshi Okada, MD PhD, Masao Kobayashi, MD PhD

Blood (2015) 126 (23): 3591.

https://doi.org/10.1182/blood.V126.23.3591.3591

Published: 2015

Journal Articles

Crosslinking of Fc Gamma-Rllb and Fc Epsilon-RI Binding Peptides Inhibits Osteoclast Formation in Multiple Myeloma through Inactivation of the ITAM Signaling Pathway

Haiming Chen, MD PhD, Mingjie Li, BS, Eric Sanchez, BA, Abigail Gillespie, BS, Cathy Wang, BS, Tiffany Lee, Suzie Vardanyan, MS, Jason Nosrati, BS, Jasmin Cao, Michael Zahab, Puja Mehta, BS, George Tang, PhD, James Berenson, MD

Blood (2015) 126 (23): 2995.

https://doi.org/10.1182/blood.V126.23.2995.2995

Published: 2015

Journal Articles

Age-Associated Bone Disease in Factor VIII-Deficient Mice

Emily A. Larson, Urszula T. Iwaniec, PhD, Sigrid C. Holmgren, MS, Russell T. Turner, PhD, Michael Recht, MD PhD, Jason A. Taylor, MD PhD

Blood (2014) 124 (21): 2798.

https://doi.org/10.1182/blood.V124.21.2798.2798

Published: 2014

Journal Articles

Effects of Cabozantinib Alone and in Combination with Bortezomib in the 5TGM1 Murine Multiple Myeloma Model

Dana T. Aftab, PhD, Mari I. Suominen, Douglas O. Clary, PhD, Rami Käkönen, Katja M. Fagerlund, Esa Alhoniemi, Jukka P. Rissanen, Jussi M. Halleen

Blood (2014) 124 (21): 3442.

https://doi.org/10.1182/blood.V124.21.3442.3442

Published: 2014

Journal Articles

The Role of LIGHT in Multiple Myeloma-Bone Disease

Giacomina Brunetti, PhD, Rita Rizzi, MD, Angela Oranger, PhD, Isabella Gigante, Giorgio Mori, PhD, Grazia Taurino, Teresa Mongelli, Graziana Colaianni, Adriana Di Benedetto, Roberto Tamma, Giuseppe Ingravallo, Anna Napoli, Anna Mestice, Paola Curci, MD, Silvia Colucci, PhD, Giorgina Specchia, MD, Maria Grano, PhD

Blood (2014) 124 (21): 3362.

https://doi.org/10.1182/blood.V124.21.3362.3362

Published: 2014

Journal Articles

The Combination of Bortezomib and Lenalidomide (VR) Consolidation Post-ASCT, in the Absence of Dexamethasone and Bisphosphonates, Improves Response Rates and Bone Metabolism in Newly Diagnosed Patients with Multiple Myeloma

Evangelos Terpos, Efstathios Kastritis, MD, Dimitrios Christoulas, Evangelos Eleutherakis-Papaiakovou, Maria Gavriatopoulou, Despoina Kalapanida, Marios Bakogeorgos, Maria Roussou, Meletios A. Dimopoulos

Blood (2014) 124 (21): 3462.

https://doi.org/10.1182/blood.V124.21.3462.3462

Published: 2014

Journal Articles

Development of a Novel Phthalimide Derivative, Preclinical Effects on High-Risk Myeloma Cells and Osteoclasts

Yutaka Hattori, MD PhD, Maiko Matsushita, MD PhD, Noriko Tabata, Hirokazu Shiheido, Hiroshi Yanagawa, PhD, Arimi Ueda, Masashi Hozumi, Shotaro Kitabatake, Daiju Ichikawa

Blood (2014) 124 (21): 5718.

https://doi.org/10.1182/blood.V124.21.5718.5718

Published: 2014

Journal Articles

Assessment of Signalling Pathways in Myeloma Bone Disease Using Selected Parameters of Bone Marow Microenvironment

Jiri Minarik, MD PhD, Patrik Flodr, MD, Tomas Pika, MD PhD, Jaroslav Bacovsky, MD PhD, Pavla Latalova, MD, Petra Pusciznova, MD, Vlastimil Scudla, prof, MD PhD

Blood (2014) 124 (21): 5679.

https://doi.org/10.1182/blood.V124.21.5679.5679

Published: 2014

NARROW

Bone Loss and High Bone Turnover in Patients with Non-Hodgkin's Lymphoma Who Receive Frontline Chemotherapy: Final Results of a Multicenter Prospective Study

Impact of Daratumumab Monotherapy on Bone Parameters in Patients with Relapsed and/or Refractory Multiple Myeloma Who Have Received at Least 2 Prior Lines of Therapy Including Lenalidomide and a Proteasome Inhibitor; Interim Analysis of a Phase 2 Study (the REBUILD Study)

Consolidation with Carfilzomib, Lenalidomide and Dexamethasone (KRd) Following ASCT Results in High Rates of Minimal Residual Disease Negativity and Improves Bone Metabolism, in the Absence of Bisphosphonates, Among Newly Diagnosed Patients with Multiple Myeloma

Myelofibrosis osteoclasts are clonal and functionally impaired

Depletion of Mature B Cells By Anti CD20-Directed Antibody Induces Trabecular Bone Loss in Young Mice: An Alert for Clinicians?

Phase 2 Study of Carfilzomib and Bone Metabolism in Patients with Relapsed Multiple Myeloma

The Combination of Radium-223 Dichloride and Bortezomib Effectively Reduces Tumor Burden and Lesion Area in the Syngeneic, Systemic 5TGM1 Multiple Myeloma Mouse Model

Low Intensity Vibration Treatment Reduces Myeloma Cell-Induced Osteoclast Formation By Inhibiting IL-6 and GFI-1 Production By MM Cells

The Exosomes-Derived EGFR Ligand Amphiregulin (AREG) Is a New Pro-Osteoclastogenic Factor in Multiple Myeloma

CCL3 Signaling Is Essential for Leukemia Progression but Dispensable for Hematopoietic Stem Cell Maintenance

Transdifferentiation of Bone Marrow Pro-B Cells into Bone-Resorbing Osteoclasts- an Unexpected Role for Erythropoietin

Lenalidomide, Adriamycin, and Dexamethasone (RAD) As Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma Who Are Eligible for Autologous Transplantation (ASCT): A Phase 2 Study from the Greek Myeloma Study Group

MSMD Patients with IFN-g-STAT1 Signaling Defect Present Enhanced Osteoclastogenesis and Bone Resorption

Crosslinking of Fc Gamma-Rllb and Fc Epsilon-RI Binding Peptides Inhibits Osteoclast Formation in Multiple Myeloma through Inactivation of the ITAM Signaling Pathway

Age-Associated Bone Disease in Factor VIII-Deficient Mice

Effects of Cabozantinib Alone and in Combination with Bortezomib in the 5TGM1 Murine Multiple Myeloma Model

The Role of LIGHT in Multiple Myeloma-Bone Disease

The Combination of Bortezomib and Lenalidomide (VR) Consolidation Post-ASCT, in the Absence of Dexamethasone and Bisphosphonates, Improves Response Rates and Bone Metabolism in Newly Diagnosed Patients with Multiple Myeloma

Development of a Novel Phthalimide Derivative, Preclinical Effects on High-Risk Myeloma Cells and Osteoclasts

Assessment of Signalling Pathways in Myeloma Bone Disease Using Selected Parameters of Bone Marow Microenvironment

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only